clinical trial · NCT07441408
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
Bristol-Myers Squibb·phase3·not yet recruiting·n = 2,277
Pulmonary FibrosisBMS-986278
brief summary
The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).
started
Dec 16, 2026
primary completion
Nov 22, 2029
completion
Mar 30, 2030
last updated
Jul 2, 2026
official title
An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol